It has been reported [1] that leukocyte extracts are capable of inhibiting the proliferation o f imm ature myelopoietic cells and this phenom enon has been brought into conjunction with models of growth regulation by feedback inhibition [2] . We wish now to report about the purification, structure and bio logical properties of a peptide m ediating such inhibitory effects and about properties o f an analo gous synthetic peptide. D etailed accounts of experi mental procedures and results as well as an exten sive docum entation of the biological experiments will be published elsewhere. Table I shows -in a schem atic way -the sequen tially applied methods which were used for the pre paration of the active peptide. This peptide (Granulopoiesis Inhibiting Factor, G IF) selectively acts upon myelopoietic proliferation in vitro (Table II) . W hen injected in vivo into mice at a rela tively low dose level a selective inhibition in the myelopoietic system is seen (com m itted stem cells and later m orphologically recognizeable cells) whereas other lineages are not significantly affected. This material is chemically homogeneous after dansylation a n d /o r [3H]carboxymethylation on Reprint requests to W. R. Paukovits.
0341-0382/82/1100-1180 $ 0 1.30/0 a) four different systems of thin layer chromatography and b) thin layer and paper electrophoresis at pH = 1 .9 and 6.5. From the electrophoretic and chromatographic behaviour of this peptide its func tional groups could be identified qualitatively and quantitatively as being a) a single prim ary aminogroup which is not the N-term inal group, b) a single thiol group and c) three carboxyl groups in addition to a pyroglutamyl residue identified earlier by en zymatic methods [3] , These results are consistent with earlier findings [4] and are corroborated by the identification of Asp, Glu, Cys and Lys in dansylated hydrolysates of GIF.
Partial acid hydrolysis of [3H]carboxymethylated G IF yielded the peptide [3H]CM-Cys-Lys-OH, the sequence of which was determ ined by [14C]dansylation and total hydrolysis [5] . The absence of Glu from this peptide identified it as the C-terminal part of G IF, the N-terminal part being then /?Glu-(A sp/G lu)-(A sp/G lu)-O H in accordance with the distribution of functional groups in the m ole cule. The structure of G IF as determ ined in this way also gives an explanation for the proteolytic stability of this peptide [6] , Based on arguments concerning the relative ease of formation of the C-terminal Cys-Lys peptide we have synthesized several of the possible candidate peptides and wish to report the results obtained with the peptide pGlu-Glu-Asp-Cys-Lys-OH (code HP5b). This peptide has been synthesized by the active ester coupling method using p-nitrophenyl and N-hydroxysuccinimide esters of BOC-protected aminoacid derivatives. Benzyl type substituents were used for protecting side chain functional groups during synthesis. After each coupling step the product was purified by chrom atography on Sephadex LH-20. The final deprotection was achieved with hydrogen brom ide in anhydrous trifluoroacetic acid and the product was purified by gel-and ion exchange chromatography.
HP5b, when acting in vitro on cultures of normal hemopoietic cells shows a strong dose dependent inhibition of myeloid colony formation whereas the formation of erythropoietic colonies was not af fected. The same preferential action was observed with permanent cell lines of myeloid and nonmyeloid origin. W hen HP5b was applied in vivo ( Fig. 1 Table II . Effects of purified G IF on in vitro colony formation and thymidine incorporation of myeloid and nonmyeloid hemic cells. Table I , step 7 (less than 10 ng) was dissolved in 1 ml of water. The relative "concentration" of this solution was set at 1 and the dilution factors given in the table are expressed relative to this solution.
Dilution Colony form ation Thymidine incorporation factor ------------------------------------------------------------------------------------------------
(CFU-c) followed by prolonged reductions of the more m ature granulocytic cells in the bone marrow, and accompanied by pronounced variations and temporary increases in the erythropoietic lineage. These effects may be the result of the transient depression of pluripotent stem cells (CFU-s) as observed after multiple or prolonged application of the peptide. The effects further extend to variations in the peripheral blood which again are dominated by a prolonged reduction of granulocyte numbers accompanied by transient changes in the lym pho cyte population. HP5b seems to act more strongly in certain dose ranges (ca. 10-5 m) as compared to others (ca. 10~8 m). Very high doses (above 10-4 m) as well as long term continuous application abolish the effects on some of the populations investigated. Table I , step 7 (less than 10 ng) was dissolved in 1 ml of water. The relative " concentration" of this solution was set at 1 and the dilution factors given in the table are expressed relative to this solution.
All hematological effects observed were reversible and no macroscopic pathological changes were ob served in the other organs of the animals. Investiga tions on the influence of HP5b on the circadian rhythm icity of the bone marrow show that the gross inhibitory action comes about by the prevention of the normal proliferative wave during the first part of the day. The results of prelim inary survival experiments with mice indicate that HP5b might be effective as a protector against the myelotoxic ef fects of certain cytostatic drugs. HP5b pretreated mice show a doubled m edian survival tim e when treated with lethal doses of cytosine arabinoside, which may be the result of the reversible anti proliferative action of the peptide at the stem cell level [7] , Although the studies leading to the preparation of HP5b originated from work on the socalled granulocytic chalone, this concept appears too nar- The work described in this paper has been gener ously supported by the G ertrud Keller Fund
